Clinical Trials Logo

Clinical Trial Summary

Coagulation dysfunction is frequent in septic patients and it is associated with an increase risk of mortality. During sepsis platelets number usually decreases and their function is reduced and this mechanism is sustained by an inflammatory induced coagulopathy. Some recent studies evaluated the possibility to use viscoelastic whole blood tests of the haemostasis, such as thromboelastography (TEG), which analyze all blood components and their interactions during clot formation and dissolution and might be useful for assessing bleeding risk in septic patients. Maximun amplitude (MA) is one of the variables obtained from TEG analysis and it expresses the strength of the clot and the efficacy of platelet function. A low level of MA describes a lower strength of the clot determined by a lower number or a reduced function of platelet.

The aim of the present study is to evaluate whether a lower level of MA and a pattern of hypocoagulability might be associated with an increased risk of bleeding and need of transfusion in patients with sepsis.

We want to conduct a prospective multicenter observational study, enrolling 100 consecutive adults patients with sepsis. We will exclude patients under 18 years old of age, chronic use of oral anticoagulant and anti platelet treatment, hematologic malignancy, congenital bleeding disorders, oral contraceptives, lack of consent.

Primary end point To evaluate whether a lower level of MA might be associated with an increased risk of bleeding.

Secondary end points: to evaluate whether a different level of MA correlates with the biomarker of the severity of sepsis such as presepsin, with the biomarker of the severity of infection and whether a pattern of hypocoagulability might be associated with a risk of mortality.

All enrolled patients will undergo a blood sample at admission (T0), after 72 hours (T1) and after 7 days (T2) and all the following parameters will be measured:

Platelet count, APTT, PT, INR, fibrinogen, procalcitonin and presepsin .

Additionally, all viscoelastic parameters (reaction time (R), clot formation speed (K), angle (alpha) and maximum amplitude (MA)) will be performed at bedside, at T0, T1, T2:

Outcome measurements: Intensive Care Unit Length of Stay and mortality at 28 days and at 90 days.


Clinical Trial Description

Introduction

Coagulation dysfunction is frequent in patients with severe sepsis and it is associated with an increase risk of mortality. During sepsis platelets number usually decreases and their function is reduced and this mechanism is sustained by an inflammatory induced coagulopathy. Several studies have showed a correlation between altered function of platelets and sepsis severity.

Conventional coagulation tests such as activated partial thromboplastin time (APTT), prothrombin time (PT) and international normalized ratio (INR) were developed mainly to monitor anticoagulation treatment and may not fully reflect the complex in vivo coagulation disturbances that usually characterizes sepsis. More recently some studies evaluated the possibility to use viscoelastic whole blood tests of the haemostasis, such as thromboelastography (TEG) and thromboelastometry (ROTEM), which analyze all blood components and their interactions during clot formation and dissolution and might be useful for assessing bleeding risk in septic patients.

A more recent study identified a possible hypocoagulability pattern among septic patients at risk of bleeding using TEG variable and the authors found a strong correlation with increased risk of death. Maximun amplitude (MA) is one of the variables obtained from TEG analysis and it expresses the strength of the clot and the efficacy of platelet function. A low level of MA describes a lower strength of the clot determined by a lower number or a reduced function of platelet. In one recent study it has been described that a lower MA describing a hypocoagulability pattern might be associated with an increased risk of death.

The aim of the present study is to evaluate whether a lower level of MA and a pattern of hypocoagulability might be associated with an increased risk of bleeding and need of transfusion in patients with sepsis.

Methods A prospective multicenter observational study will be conducted in five intensive care units of five Italian university hospitals. We asked for Ethic Committee approval.

Inclusion criteria: : all adult patients with diagnosis of sepsis admitted for more than 48 hours will be enrolled.

Exclusion criteria: patients younger than 18 years old of age; chronic use of oral anticoagulant and anti platelet treatment; hematologic malignancy; congenital bleeding disorders; oral contraceptives; lack of consent.

Primary end point To evaluate whether a lower level of MA might be associated with an increased risk of bleeding.

Secondary end points

1. To evaluate whether a different level of MA correlates with the biomarker of the severity of sepsis such as presepsin (PSEP).

2. To evaluate whether a different level of MA correlates with the biomarker of the severity of infection such as procalcitonin (PCT).

3. To evaluate whether a pattern of hypocoagulability might be associated with a risk of mortality.

Study Design Prospective, multicenter, observational

All demographic and clinical data will be collected for each patient, as following:

Age, gender, weight, simplify acute physiology score (SAPS) II, sequential organ failure assessment (SOFA) score (at admission and every 72 hours), clinical pulmonary infection score (CPIS), if the source of infection comes from lung, type of infection and microbiological isolation, haemodynamic parameters (heart rate, mean arterial pressure, pulmonary capillary wedge pressure, cardiac output, mixed venous oxygen saturation) and renal function (creatinine, urine output and fluid balance).

All enrolled patients will undergo a blood sample at admission (T0), after 72 hours (T1) and after 7 days (T2) and all the following parameters will be measured:

Platelet count, APTT, PT, INR, fibrinogen, procalcitonin and presepsin.

Additionally, all viscoelastic parameters will be performed at bedside, using a TEG 5000 Hemostasis Analyzer System (Haemoscope Corporation, Chicago, Illinois, USA), at T0, T1, T2:

1. reaction time (R), normal range (3-8 sec)

2. clot formation speed (K), normal range (1-3 sec)

3. angle (alpha), which reflects the clot growth kinetics, normal range (55-75°)

4. maximun amplitude (MA), normal range (51-69 mm)

5. fibrinogen maximun amplitude (FFMA), normal range (14-24 mm)

Bleeding definition We defined bleeding event as any intracranial bleeding identified at CT scan or any other bleeding at gastrointestinal tract (hematemesis or melena or frank blood in the stools), at tracheal aspirates or in the urine or bleeding during surgery and from wounds or any bleeding event requiring concomitant transfusion of three units of red blood cells.

Outcome measurements

1. Intensive Care Unit Length of Stay (ICU-LOS);

2. Mortality at 28 days and at 90 days.

Statistical analysis A power analysis was calculated considering primary endpoint: correlation between level of MA and risk of bleeding.

We defined bleeding as intracranial, gastrointestinal, tracheal or surgical bleeding or any bleeding event requiring concomitant transfusion of three units of red blood cells. From previous study we observed an incidence of 26%.

Power 86.4% B (size of the regression coefficient) 0.1 Standard deviation of MA 6 P (event rate) 26% Alpha 0.05

The expected number of patients enrolled in 24 months is about 100 and with a Cox proportional hazard model we can estimate the Hazard Ratios (HR) and 95% CI with the parameters of the following table.

A Cox regression of the log hazard ratio on MA as a covariate with a standard deviation of 6, based on a sample of 100 observations achieves 86.4% power at a 0.05 significance level to detect a regression coefficient equal to 0.1 (log of hazard ratio). The sample size was adjusted for a bleeding rate of 26%.

The characteristics of the patients and clinical measures will be describe using the most appropriate statistics, as mean (SD), median (IQR) or percentages according to variable type and distribution.

The cumulative incidence of bleeding during period of observation (7 days) will be estimated with the Gooley method, to take into account the competitive risk of death, and compared with the Gray test. The Fine and Grey model will be used to estimate adjusted HR and their 95% CI.

Evaluation of associations between MA and severity of disease or infection will be assessed using Spearman's correlation test. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03095625
Study type Observational [Patient Registry]
Source University of Turin, Italy
Contact Luca Brazzi, MD
Phone +39 011 633
Email luca.brazzi@unito.it
Status Recruiting
Phase N/A
Start date October 1, 2015
Completion date December 31, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3